NTLA - Intellia Therapeutics, Inc.

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 24.46

Open

$ 25.02

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 24.25 - $ 25.39

52 Week Range

$ 19.37 - $ 47.48

Volume

2,042,656

Average Volume

Market Cap

2.34B

Beta (5Y Monthly)

$ 1.56

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	02-22-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-23-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-26-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	02-27-2020	12-31-2019	10-K
19	10-31-2019	09-30-2019	10-Q
20	08-01-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	02-27-2019	12-31-2018	10-K
23	10-31-2018	09-30-2018	10-Q
24	08-01-2018	06-30-2018	10-Q
25	05-01-2018	03-31-2018	10-Q
26	03-14-2018	12-31-2017	10-K
27	10-31-2017	09-30-2017	10-Q
28	08-01-2017	06-30-2017	10-Q
29	05-02-2017	03-31-2017	10-Q
30	03-14-2017	12-31-2016	10-K
31	11-01-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	06-03-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Citigroup Maintains Neutral on Intellia Th...
05/10/2024 21:34:12

Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target fr...

BMO Capital Maintains Outperform on Intell...
05/10/2024 15:07:51

BMO Capital analyst Kostas Biliouris maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price ta...

Intellia Therapeutics' Q1 Cash, Cash Equiv...
05/09/2024 11:33:55

Intellia Therapeutics Q1 2024 GAAP EPS $(1...
05/09/2024 11:32:25

Intellia Therapeutics Announced The Accept...
04/29/2024 11:31:35

Wedbush Reiterates Neutral on Intellia The...
04/23/2024 17:11:21

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $29 price tar...

Intellia Therapeutics On March 19, Notifie...
03/22/2024 13:29:44

-SEC Filing

Intellia Therapeutics Announces First Pati...
03/18/2024 11:35:57

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...

cathie-woods-ark-invest-offloads-69m-worth-of-coinbase-robinhood-shares-each-amid-searing-bitcoin-rally--nvidia-stock-also-shed

Cathie Wood's Ark Invest Offloads $6.9M Wo...
02/27/2024 03:45:00

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such a...

Goldman Sachs Downgrades Intellia Therapeu...
02/23/2024 18:34:33

Goldman Sachs analyst Salveen Richter downgrades Intellia Therapeutics (NASDAQ:NTLA) from Buy to Neutral and announces $32 p...

Canaccord Genuity Maintains Buy on Intelli...
02/23/2024 14:54:24

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target ...

Intellia Therapeutics' Cash, Cash Equivale...
02/22/2024 12:38:53

Intellia Therapeutics Q4 EPS $(1.46) Misse...
02/22/2024 12:36:42

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate ...

Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

A Preview Of Intellia Therapeutics's Earnings
02/21/2024 16:01:27

Intellia Therapeutics, ReCode Therapeutics...
02/15/2024 12:34:22

CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestiv...

Wolfe Research Initiates Coverage On Intel...
02/15/2024 11:35:54

Wolfe Research analyst Andy Chen initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Peer Perform rating.

not-shy-of-buying-the-dip-cathie-woods-ark-mops-up-over-11m-worth-of-shares-in-tesla--sells-nvidia-stock

Not Shy Of Buying The Dip, Cathie Wood's A...
02/06/2024 03:45:45

cathie-woods-ark-invest-snatches-up-47m-more-in-tesla-shares-invests-equally-in-this-rocket-company

Cathie Wood's Ark Invest Snatches Up $4.7M...
02/02/2024 04:18:45

Intellia Therapeutics Reveals Publication ...
01/31/2024 22:09:21

The company said data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary ang...